Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

585 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cluster analysis of genomic ETV6-RUNX1 (TEL-AML1) fusion sites in childhood acute lymphoblastic leukemia.
von Goessel H, Jacobs U, Semper S, Krumbholz M, Langer T, Keller T, Schrauder A, van der Velden VH, van Dongen JJ, Harbott J, Panzer-Grümayer ER, Schrappe M, Rascher W, Metzler M. von Goessel H, et al. Among authors: van der velden vh, van dongen jj. Leuk Res. 2009 Aug;33(8):1082-8. doi: 10.1016/j.leukres.2008.11.001. Epub 2008 Dec 10. Leuk Res. 2009. PMID: 19081626
Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting.
van der Velden VH, Panzer-Grümayer ER, Cazzaniga G, Flohr T, Sutton R, Schrauder A, Basso G, Schrappe M, Wijkhuijs JM, Konrad M, Bartram CR, Masera G, Biondi A, van Dongen JJ. van der Velden VH, et al. Among authors: van dongen jj. Leukemia. 2007 Apr;21(4):706-13. doi: 10.1038/sj.leu.2404535. Epub 2007 Feb 8. Leukemia. 2007. PMID: 17287857
Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia.
Flohr T, Schrauder A, Cazzaniga G, Panzer-Grümayer R, van der Velden V, Fischer S, Stanulla M, Basso G, Niggli FK, Schäfer BW, Sutton R, Koehler R, Zimmermann M, Valsecchi MG, Gadner H, Masera G, Schrappe M, van Dongen JJ, Biondi A, Bartram CR; International BFM Study Group (I-BFM-SG). Flohr T, et al. Among authors: van dongen jj, van der velden v. Leukemia. 2008 Apr;22(4):771-82. doi: 10.1038/leu.2008.5. Epub 2008 Jan 31. Leukemia. 2008. PMID: 18239620 Clinical Trial.
Bimodal distribution of genomic MLL breakpoints in infant acute lymphoblastic leukemia treatment.
Jung R, Jacobs U, Krumbholz M, Langer T, Keller T, De Lorenzo P, Valsecchi MG, van der Velden VH, Moericke A, Stanulla M, Teigler-Schlegel A, Panzer-Gruemayer ER, van Dongen JJ, Schrappe M, den Boer ML, Pieters R, Rascher W, Metzler M. Jung R, et al. Among authors: van der velden vh, van dongen jj. Leukemia. 2010 Apr;24(4):903-7. doi: 10.1038/leu.2010.14. Epub 2010 Feb 18. Leukemia. 2010. PMID: 20164851 No abstract available.
Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR.
van der Velden VH, Willemse MJ, van der Schoot CE, Hählen K, van Wering ER, van Dongen JJ. van der Velden VH, et al. Among authors: van dongen jj, van der schoot ce, van wering er. Leukemia. 2002 May;16(5):928-36. doi: 10.1038/sj.leu.2402475. Leukemia. 2002. PMID: 11986956
Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.
van der Velden VH, Jacobs DC, Wijkhuijs AJ, Comans-Bitter WM, Willemse MJ, Hählen K, Kamps WA, van Wering ER, van Dongen JJ. van der Velden VH, et al. Among authors: van dongen jj, van wering er. Leukemia. 2002 Aug;16(8):1432-6. doi: 10.1038/sj.leu.2402636. Leukemia. 2002. PMID: 12145681
585 results